Particularly in dual pathology models combining T2DM and AD, SGLT2is not only enhance insulin sensitivity but also significantly reduce β-amyloid deposition, addressing two fundamental pathological hallmarks of AD. This evidence concerns the gene INS and type 2 diabetes mellitus.